2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 783

Differences in Chromatin Architecture in Treatment Naïve Pediatric Lupus Patients
Abstract Number: 2489

Differences in Clinical Characteristics, Quality of Life, Disability, and Work Productivity in Psoriatic Arthritis Patients by Gender: Findings from a Cross-sectional Survey in the US and Europe
Abstract Number: 1156

Differences in Clinical Outcomes According to the Healthcare Regime in Colombian Patients with Rheumatoid Arthritis
Abstract Number: 425

Differences in Correlation Between Objective Disease Measurements and Patient’s/physician’s Global Assessment in the Large Non-interventional Study SUSTAIN
Abstract Number: 2229

Differences in Fracture Risk Assessment (FRAX) and Osteoporosis Treatment Cutoffs with and Without Bone Mineral Density Are Greater in Anti-Cyclic Citrullinated Peptide Positive Rheumatoid Arthritis
Abstract Number: 2090

Differences in Stepping and Standing Based on Self-reported Exercise Identity in Persons Following Total Knee Replacement
Abstract Number: 2818

Differences in the Phenotypic Landscape and Antigen Specificity of CD4+ T Cells Are Present in CCP+ Subjects Before the Onset of Rheumatoid Arthritis
Abstract Number: 1268

Different Colchicine Preparations for Familial Mediterranean Fever: Are They the Same?
Abstract Number: 1839

Different Patterns and Specific Outcomes of Large-Vessel Involvements in Giant Cell Arteritis
Abstract Number: 2598

Different Treatment Backgrounds Do Not Influence Aminaphtone Efficacy in Primary and Secondary Raynaud’s Phenomenon
Abstract Number: 2504

Differential Expression of Human Endogenous Retroviruses in Psoriatic Disease
Abstract Number: 2738

Differential Methylation of Peripheral Blood Adaptive Immune Cells in Individuals at High Risk for RA and with Early RA Compared with Controls Identifies Pathways Important in Transition to Arthritis
Abstract Number: 697

Differing Opinions on Clinical Research Between Healthcare Providers and Lupus Patients
Abstract Number: 726

Digital Blood Perfusion Differences Between Black Africans and Caucasians with Systemic Sclerosis
Abstract Number: 2746

Dimethyl Fumarate Ameliorates the GATA6 Deficiency-Induced Pulmonary Hypertension by Normalizing Oxidative and ER Stress

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].